PharmaCyte Biotech ( NASDAQ: PMCB ) announced a $7 million investment in MyMD Pharmaceuticals ( NASDAQ: MYMD ), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions. PharmaCyte’s investment in externally developed technology solidifies its strategy to prudently apply its approximately $65 million (as of March 31, 2024) cash position. Source: Press Release More on MyMD Pharmaceuticals, PharmaCyte Biotech, Inc.
, etc. Financial information for MyMD Pharmaceuticals Financial information for PharmaCyte Biotech, Inc..
